The International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction is a project led by eviQ and the Cancer Institute NSW.
This guideline aims to be a supportive decision-making tool by providing an accepted practical, transparent and standardised approach for the management of anticancer drug dosing in kidney dysfunction based on current evidence and clinical consensus. The final guideline will include recommendations for 59 anticancer drugs.
The working party includes multidisciplinary experts in oncology, haematology, nephrology, pharmacology and geriatrics, with participation from Kidney Disease Improving Global Outcomes (KDIGO), International Society of Geriatric Oncology, British Oncology Pharmacy Association, International Society of Oncology Pharmacy Practitioners, Cancer and the Kidney International Network, National Cancer Institute’s Organ Dysfunction Working Group.
External consultation of the completed draft guideline is planned for September 2021.
Once finalised and published, eviQ will incorporate the guideline recommendations into each of its drug treatment protocols beginning early 2022. This will be preceded by a comprehensive communication plan to all eviQ users.
Three draft recommendations for a standardised approach to assessing kidney function in cancer patients and subsequent dose adjustments in kidney dysfunction achieved consensus at a national workshop on 14 December 2020. This workshop involved 56 participants from around the world including leading experts in nephrology, oncology, haematology, clinical pharmacology, geriatrics and chemical pathology, as well as key national stakeholders representing medical groups and regulatory bodies.